Brain cancer experts crowdsource a cure for deadly glioblastoma

November 12, 2015

One hundred and thirty clinicians and researchers from major cancer centres from around the world will meet in Washington, DC on Thursday to crowdsource a way to design an ambitious clinical trial aimed at rapidly identifying a cure for the world's deadliest and most common brain cancer, glioblastoma.

"This will be a Silicon Valley approach to medical research," says medical oncologist Dr Mustafa Khasraw, the Australian liaison for the study who will attend this week's meeting in Washington. "We want to fail early and fail often so we can rapidly discriminate between effective and ineffective therapies," says Dr Khasraw, a senior research fellow at the University of Sydney's Clinical Trials Centre.

Glioblastoma is a malignant brain tumour that grows and spread aggressively, overpowering healthy cells by consuming their space, blood and nutrients. About 1500 Australians and 12000 Americans are diagnosed with glioblastoma each year. It has one of the poorest of all cancer outcomes--one in five cases survive two years from diagnosis--and no effective therapies have been developed for more than a decade, despite hundreds of clinical trials of new drugs and technologies.

The collaboration, known as GBM AGILE (an Adaptive, Global, Innovative Learning Environment) is a large international adaptive clinical trial--so-named because clinicians and researchers will adapt and change drugs, doses and other aspects of the trial based on early feedback and results, rather than waiting years to make conclusions.

Dr Khasraw says the new line of attack against glioblastoma can be summarised in three words - disrupt, cure and collaborate.

"We'll be disrupting many of the traditional methods used in clinical trials," he says. "We will be applying the latest methods of trial design in the hope that multiple treatments can be tested within the same trial protocol, to accelerate drug evaluation far beyond current research methods. That's because we want to learn as much as possible from every patient--about treatments, combinations of treatments, and biomarkers--and ultimately use that knowledge for effective treatment for all glioblastoma patients.

"Given that there have been no therapeutic breakthroughs to date we are completely focused on developing a cure for this deadly disease. To do that we need break down the silos of information that hinder rapid progress. This will be an enormous international collaboration, including a relatively large number of patients who will be enrolled into multiple arms of an adaptive trial using Bayesian statistics to assess efficacy of many new agents or treatment approaches at the same time. This will allow much faster assessment of new potentially useful therapies."

University of Sydney

Related Glioblastoma Articles from Brightsurf:

A therapeutic option for glioblastoma using pH-sensitive nanomicelles
A polymeric nanomicelle that effectively delivers to glioblastoma (GBM) was developed.

Experimental glioblastoma therapy shows curative powers in mice models
Houston Methodist researchers used a second-generation prodrug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given the newly developed prodrug.

Molecules responsible for radio-resistant glioblastoma identified
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.

Study suggests new approach to improve radiation therapy resistance in glioblastoma
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, an aggressive type of brain tumor.

Scientists ID gene responsible for deadly glioblastoma
The discovery of the oncogene responsible for glioblastoma could be the brain cancer's Achilles' heel, one researcher says.

Deconstructing glioblastoma complexity reveals its pattern of development
Brain cancers have long been thought of as being resistant to treatments because of the presence of multiple types of cancer cells within each tumor.

Surveillance after surgery does not improve outcomes for patients with glioblastoma
A retrospective study from the University of Missouri School of Medicine and MU Health Care showed patients who underwent surveillance imaging after surgery for brain tumor resection did not have better outcomes than patients who did not have imaging and returned when they felt symptoms of recurrence.

Targeting stromal cells may help overcome treatment resistance in glioblastoma
The deadly brain cancer glioblastoma (GBM) is often resistant to chemotherapy and radiation, but new research shows targeting stromal cells -- the cells that serve as the connective tissue of the organs -- may be an effective way of overcoming that resistance.

Researchers identify immune-suppressing target in glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.

Ultrasound blasts potent glioblastoma drug into brain tumor
A potent drug for glioblastoma can't be used in patients.

Read More: Glioblastoma News and Glioblastoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to